WT1 and acute myeloid leukemia: High WT1 expression was observed in 9 of 25 patients (36%), 4 of 9 (44.4%), 2 of 5 (40%), 8 of 11 (72.7%), 12 of 13 (92.3%), 15 of 16 (93.8%), and 1 of 1 (100%) in the RA, RCMD, RARS, RAEB-1, RAEB-2, AML-MDS, and 5q- categories, respectively.